The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Alterity Therapeutics Limited(NASDAQ:ATHE) 
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It i...
Website: http://www.alteritytherapeutics.com
Founded: 1997
CEO: David Stamler
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
Alterity Therapeutics Days Payable Outstanding ttm (DPO)
Alterity Therapeutics Days Receivable Outstanding ttm (DSO)
Alterity Therapeutics Days Inventory Outstanding ttm (DIO)
Alterity Therapeutics Op Cashflow Per Share ttm
Alterity Therapeutics Free Cashflow Per Share ttm
Alterity Therapeutics Cash Per Share ttm
Alterity Therapeutics P/S ratio ttm
Alterity Therapeutics (GAAP) P/E ratio ttm
Alterity Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.